Clinical Trial Update: Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

View source ↗

Summary

A clinical trial investigating PET/CT as a predictor of neoadjuvant immunotherapy efficacy in non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer (NSCLC), Neoadjuvant Immunotherapy | Status: WITHDRAWN